Multiple Myeloma Research Foundation (MMRF) Endurance Event Program Raises Over $1.4 Million for Cancer Research in 2010

Registration is now open for the 2011 MMRF Endurance Events

Norwalk, Conn. — January 19, 2011

The Multiple Myeloma Research Foundation (MMRF), one of the nation’s leading cancer research organizations, today announced that its 2010 Endurance Events program raised more than $1.4 million to support research efforts aimed at accelerating the development of new treatments for patients with multiple myeloma, an incurable blood cancer. In 2010, the Endurance Events program had a total of 435 athletes join the MMRF PowerTeam for marathons, triathlons, and cycling events across the country. Since its inception, the MMRF’s Endurance Events Program has raised more than $3 million for research.

"The success of the MMRF Endurance Events Program lies in the passion of each person who commits to not only take on the challenge of these world-class events, but to also raise funds to make a difference in the lives of multiple myeloma patients,” said Alicia O’Neill, MMRF Endurance Events Program Director. “Nearly 90% of all funds raised are directed to research and related programming. By raising funds for the MMRF while training for these premier athletic events, team members tap into their power to make the difference in the search for a cure."

Funds raised by the MMRF have accomplished outstanding milestone achievements such as helping to bring four new myeloma drugs to market, more than doubling the patient life expectancy post-diagnosis around the globe, opening 30 clinical trials 60% faster than the industry standard in oncology, and sequencing the multiple myeloma genome. Yet, the five year survival rate for myeloma remains one of the lowest of all cancers. The funds raised by the MMRF are critical in continuing to advance the progress being made.

In 2011, the MMRF Endurance Events Program will form teams for over 20 events, including triathlons, cycling events, marathons, half-marathons, and select shorter distance races nationwide. The MMRF Endurance Events program is actively recruiting more than 600 team members to reach our 2011 goal of raising $1.6 million for myeloma research. New to the lineup of events for 2011 is the Empire State Building Run-Up Powered by the MMRF, which will take place February 1, 2011.  As the presenting sponsor and benefiting charity of the event, the MMRF has 100 exclusive entries to this premier event.

Interested runners, cyclists and triathletes are already registering for events on the 2011 MMRF Endurance Events calendar. For more information on the MMRF Endurance Events Program or to reserve your spot on a 2011 MMRF Endurance Events team, please visit www.MMRFRunBikeSwim.org, email enduranceevents@themmrf.org or call 203-652-0216.

About the Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma.  The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure.  As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $150 million since its inception to fund nearly 120 laboratories worldwide, including 60 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated 30 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC).  As exceptional stewards of its donor’s investments, the MMRF consistently surpasses its peers in fiscal responsibility.  For more information about the MMRF, please visit: www.themmrf.org.

About Multiple Myeloma

Multiple myeloma is a type of blood cancer that originates in plasma cells.  It is the most common type of white blood cell cancer and the second most common blood cancer.  In 2010, more than 20,000 adults in the United States were estimated to be diagnosed with multiple myeloma and nearly 11,000 people were predicted to die from the disease.